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Abstract The “wait and see” approach in acute otitis
media (AOM), consisting of postponing the antibiotic
administration for a few days, has been advocated mainly
to counteract the increased bacterial resistance in respirato-
ry infections. This approach is not justified in children less
than 2 years of age and this for several reasons. First, AOM
is an acute inflammation of the middle ear caused in about
70% of cases by bacteria. Redness and bulging of the
tympanic membrane are characteristic findings in bacterial
AOM. Second, AOM is associated with long-term dys-
function of the inflamed eustachian tube (ET), particularly
in children less than 2 years of age. In this age group, the
small calibre of the ET together with its horizontal direction
result in impaired clearance, ventilation and protection of
the middle ear. Third, recent prospective studies have
shown poor long-term prognosis of AOM in children
below 2 years with at least 50% of recurrences and
persisting otitis media with effusion (OME) in about 35%
6 months after AOM. Viruses elicit AOM in about 30% of
children. A prolonged course of AOM has been observed
when bacterial and viral infections are combined because
viral infection is also associated with ET dysfunction in
young children. Bacterial and viral testing of the nasopha-
ryngeal aspirate is an excellent tool both for initial
treatment and recurrence of AOM. Antibiotic treatment of
AOM is mandatory in children less than 2 years of age to
decrease inflammation in the middle ear but also of the ET
particularly during the first episode. The best choice is
amoxicillin because of its superior penetration in the middle
ear. Streptococci pneumoniae with intermediary bacterial
resistance to penicillin are particularly associated with
recurrent AOM. Therefore the dosage of amoxicillin should
be 90 mg/kg per day in three doses. In recurrent AOM with
β-lactamase-producing bacilli, amoxicillin should be asso-
ciated with clavulanic acid at a dose of 6.4 mg/kg per day.
The duration of the treatment is not established yet but
10 days is reasonable for a first episode of AOM. OME
may be a precursor initiating AOM but also a complication
thereof. OME needs a watchful waiting approach. When
associated with deafness for 2–3 months in children over
2 years of age, an antibiotic should be given according to
the results of the bacterial resistance in the nasopharyngeal
aspirate. The high rate of complications of tympanostomy
tube insertion outweighs the beneficial effect on hearing
loss. The poor results of this procedure are due to the
absence of effects on ET dysfunction. Pneumococcal
vaccination has little beneficial effects on recurrent AOM
and its use in infants needs further studies. Treatment with
amoxicillin is indicated in all children younger than 2 years
with a first episode of AOM presenting with redness and
bulging of the tympanic membrane. Combined amoxicillin
and clavulanic acid should be given in patients with β-
lactamase-producing bacteria. The duration of treatment is
estimated to be at least 10 days depending on the findings
by pneumo-otoscopy and tympanometry. Bacterial and viral
testing of the nasopharyngeal aspirate is highly recom-
mended particularly in children in day care centres as well
as for regular follow-up. The high recurrence rate is due to
the long-lasting dysfunction of the eustachian tube and the
immune immaturity of children less than 2 years of age.
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Introduction
The number of publications relating to acute otitis media
(AOM) and otitis media with effusion (OME) has been
increasing markedly within the last 2 years [40–49]. It
points to the difficulties in giving generally accepted
guidelines for treatment. The confusion can be partially
explained by the absence of uniform definitions and
inhomogeneous groups of patients being included in
clinical studies.
AOM is an acute inflammation of the middle ear,
frequently elicited by viral infections and characterized by
redness and bulging of the tympanum. Infections with
bacteria can be identified in at least 70% of the cases by
culture of the middle ear purulent fluid containing mainly
polymorphonuclear cells [35].
OME is an effusion of the middle ear without symptoms
of acute inflammations such as pain and fever, with
frequently an amber or opaque aspect of the tympanum,
the effusion containing mainly macrophages. Retraction of
the tympanum with the light reflex still present may
render the diagnosis difficult. Cultures for bacteria are
positive in about 50% of cases whereas viruses have been
identified in about 30% [35]. OME may be a precursor
event initiating suppurate AOM but it can be the continuum
of AOM as well. OME is the direct consequence of
impaired middle ear ventilation.
Tympanometry (Fig. 1) shows a flat curve type b in both
AOM and OME. In contrast, in OME associated with
incomplete obstruction of the eustachian tube (ET) a curve
c with a peak in the negative pressure zone is observed.
Moreover, lower peak height and greater width in the
negative pressure zone are frequent findings in OME [54].
This overview summarizes the main new findings about
AOM and OME which are in accordance with some basic
well-known but sometimes forgotten data and facts, with
particular emphasis on the vulnerability of young children
below the age of 2 years.
Fig. 1 The three main types of tympanograms showing: a a peak near
atmospheric pressure expressed in daPa with stapedius reflex for
different Hz frequencies, b a flat curve without stapedius reflex for
500, 2000, 4000 Hz pointing to presence of middle ear exudate: AOM
or OME, c a lower peak in the negative pressure zone (−235 daPa)
with an enlarged width pointing to OME with partial permeability of
ET to air entrance and still a stapedius reflex
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Role of the eustachian tube
The great importance of the first attack of AOM in young
children lies in the subsequent long-lasting dysfunction of
the ET. Indeed, the main functions of the ETare ventilation,
protection and clearance of the middle ears (Fig. 2)[ 5, 35]
and play a determining role in the recurrence of AOM.
Ventilation of the middle ear occurs by each deglutition by
action of the tensor velum palatinum muscle leading to air
equilibration with the atmospheric pressure. By obstruction
of the ET, a negative pressure develops inside the middle
ear resulting in effusion and aspiration of nasopharyngeal
secretions. Poor ventilation leads to decreased PO2 which
results in decreased bactericide power of polymorphonu-
clear cells. Impaired clearance results in proliferation not
only of aerobic but also anaerobic bacteria in the middle
ear. Conversely, reflux otitis occurs with decreased compli-
ance of the ET due to abnormal flaccidity.
ET dysfunction is a major problem in the young child: the
small calibre of the ET as well as its horizontal direction [5]
(Figs. 3 and 4) are responsible for both the high incidence of
AOM and the frequent relapses by each viral infection. This
explains the poor long-term prognosis evidenced in a
prospective study comprising 210 AOM patients of less
than2years ofagebyDamoiseauxetal.[16].Atleast50%of
the patients had recurrences of AOM and persistence of OME
was observed in 47% of them after 3 months and in 35% after
6 months. Yet, only 50% of these patients were treated with
amoxicillin. Unfortunately, the authors do not mention either
the delay of treatment or the dosage of the antibiotic.
In other words, the first episode of AOM determines the
evolution and the recurrences because of the associated
acute inflammation involving also the ET.
Role of viruses and bacteria
Viruses
Most children are infected with respiratory syncytial virus
(RSV) in their first year of life. A prospective study [2]i n
42 children aged 2–24 months with bronchiolitis showed
that 26 of them had AOM at entry or within 10 days and an
additional 10 developed OME; only 6 patients remained
free of both AOM and OME during a 3-week observation
period. These findings were confirmed in a recent study
showing that in patients with persistent RSV antigen in the
middle ear effusion, 31% relapsed despite a favourable
outcome of the first AOM episode [50].
The association of AOM with several viral infections has
been largely documented. The prevalence of respiratory
viruses in the middle ear fluid of 456 children, aged
7 months to 7 years, with AOM was 41% [21]. RSV was
the most frequent virus isolated followed by parainfluenza,
influenza, enteroviruses and adenoviruses. These findings
have been confirmed by others [18, 32, 33, 41, 50] and
rhinovirus, coronavirus and metapneumovirus should be
added to the above-mentioned list [53]. Even the measles
virus has recently been isolated from the middle ear fluid in
two patients [64].
Bacteria
In 70% of patients with AOM, bacteria can be found by
culturing the middle ear fluid [35]. The most frequent species
isolated are Haemophilus influenzae and Streptococcus
pneumoniae [27]. Nasopharyngeal aspirate culture may give
valuable information on the bacteria involved in AOM [28,
51, 55, 58]. The presence of conjunctivitis points to
Haemophilus influenzae infection [4].
Heikkinen et al. found Streptococcus pneumoniae in
25% of their patients, Haemophilus influenzae in 23% and
Fig. 2 Three physiologic func-
tions of the eustachian tube in
relation to the middle ear. NP
nasopharynx, ET eustachian
tube, TVP tensor velum palati-
num muscle, ME middle ear,
MAST mastoid, TM tympanic
membrane, EC external canal
Eur J Pediatr (2007) 166:511–519 513Moraxella catarrhalis in 15% [21]. It has been demonstrat-
ed that recurrences of AOM are associated with positive
bacterial culture in the nasopharynx [23], even at the end of
the antibiotic treatment [28] and in most cases the pathogen
was Streptococcus pneumoniae [58]. However, recurrence
more than 14 days after an initial AOM episode is mostly
due to a new infection, i.e. not a true relapse [27]. In a most
recent prospective study on purulent meningitis [11], the
association of AOM was found in half of the patients [14].
Bacteria and viruses
Bulut et al. performed both bacterial and viral testing in 120
children with AOM [8]. These patients, aged between
Fig. 3 The difference in the
angle of the eustachian tube
between infants and adults [5]
Fig. 4 The tympanic membrane
forms the lateral wall of the box-
shaped middle ear. The function
of the eustachian tube is to
equilibrate middle ear pressure
with that in the nasopharynx.
Bacteria and viruses resident in
the nasopharynx may reach the
middle ear during pressure
equilibration. One-third of the
middle ear mucosa and the
entire eustachian tube are lined
with mucociliary epithelium to
transport bacteria from the mid-
dle ear back to the nasopharynx.
Air from the middle ear enters
the mastoid air cells by way of
the aditus
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2 weeks prior to the study. A positive bacterial culture was
obtained in 54% of the children and respiratory viruses
were identified in 32% of them; combined viral and
bacterial infection was demonstrated in 12% of the samples.
Persistent otitis was documented in about 50% of the
children with combined viral and bacterial infection in a
prospective study of 271 children because viral infections
contribute to the ET dysfunction [12].
Other risk factors
The immaturity of the immune system of young children
makes them incapable of killing encapsulated bacteria.
This, along with the ET dysfunction, explains the long-
lasting course of AOM as well as the high recurrence rate.
This is particularly important for infants attending day
care centres [37, 38]. It is sometimes necessary to withdraw
these infants from these institutions during the winter to
avoid recurrences. Additional risk factors are passive
smoking, young siblings going to school and siblings with
previous AOM episodes.
These factors were identified in a prospective study on
2,253 children aged 2 months to 2 years published in 1997
[37]. The proportion of patients developing at least one
episode of OME was 79% at 12 months and 91% at
24 months. Breast feeding and exposure to tobacco smoke
contributed little to the outcome, but a lower socioeconomic
status and repeated exposure to other children at home or in
day care centres were the most important risk factors.
Childrenwithcleftpalateareparticularlypronetootitisand
should be treated by early tympanostomy tube insertion [60].
Complications: mastoiditis
Mastoiditis should be treated by antibiotics according to the
bacterial resistance and by temporarily inserting tympanos-
tomy tubes to improve drainage [65] because of the narrow
calibre of the aditus ad antrum. [22] (Fig. 4).
Treatment
General considerations
A “wait and see” approach has been advocated in the
treatment of AOM in children mainly because of the
increased antimicrobial resistance of bacteria causing
respiratory infections [13]. Indeed, a meta-analysis of
5,400 children, aged 6 months to 18 years, and collected
from 33 randomized trials concluded that there was a
significant but modest impact of antibiotics on the primary
control of AOM [45]. Similar results emerged from a
subsequent study published by Damoiseaux et al. in 2000
[15]. This randomized double-blind prospective trial carried
out by general practitioners in 240 children, aged 6 months
to 2 years, showed that only 7 and maybe 8 of them needed
antibiotics. Both studies, however, suffer from major flaws;
the absence of long-term data, in particular the recurrence
rate of AOM, and OME not being considered an end point.
Moreover, the former study included patients with a very
large age range and therefore blunted the effect of the
critical age group of the patients below the age of 2 years.
Indeed, over 70% of AOM patients present their first attack
during the first year of life and over 90% within 2 years of
age [35]. The visualisation of the tympanum in this age
group is not always easy especially when cerumen obstructs
the narrow external ear channel. Yet, as already mentioned
above, bulging and redness of the tympanic membrane are
important diagnostic signs of bacterial AOM [27, 39].
Treatment of AOM
The crucial role of the first attack of AOM makes the
immediate administration of antibiotics mandatory in all
patients with AOM with redness and a bulging tympanum
(Table 1)[ 26]. A “wait and see” approach can only increase
the inflammation and hence the ET dysfunction. The choice
of the antibiotic must take into account the penetration in
the middle ear and the type of bacteria involved. The
Table 1 Guidelines for treatment of AOM
Episode Signs or symptoms Treatment or approach
Children <2 years of age
First episode Amoxicillin 90 mg/kg per day for at least 10 days according to the bacterial resistance
Weekly follow-up by tympanometry and pneumo-otoscopy
Recurrent
episode
With redness and bulging tympanum Amoxicillin or amoxicillin 90 mg/kg per day + clavulanic acid 6.4 mg/kg per day
according to bacterial resistance
Without bulging “Wait and see” approach
Children >2 years of age
With redness and bulging tympanum
or otorrhoea
Same treatment as “recurrent episode”
Without evident bulging tympanum “Wait and see” approach
Eur J Pediatr (2007) 166:511–519 515penetration for amoxicillin—about 40% of the blood
concentration—is much higher than for cephalosporins
(about 20%) and macrolides (about 10%) but lower than
for cotrimoxazole (60%) [31]. The penetration of amoxi-
cillin is not changed by the addition of clavulanate to
amoxicillin [10, 52].
Because of the increased incidence of Streptococcus
pneumoniae with intermediary resistance [57, 61], the
dosage of amoxicillin should be doubled, i.e. 90 mg/kg
per day given in three administrations as recommended by
the Centers for Disease Control and Prevention [3].
Haemophilus influenzae is more likely to become β-
lactamase positive after previous antibiotic administration
[9]. Therefore, the addition of clavulanate—at a dose of
6.4 mg/kg per day—to amoxicillin makes sense. Most
Moraxella catarrhalis strains are nowadays also β-lacta-
mase positive [42].
The duration of the antibiotic treatment is a matter of
discussion. For children less than 2 years of age, a 10-day
course is reasonable. Pneumo-otoscopy and tympanometry
can help to appreciate the permeability of the ET. Careful
follow-up is necessary.
Nasopharyngeal aspirate cultures may give valuable
results and are highly recommended in children remaining
in day care centres or with a history of previous AOM
episodes [28, 51].
For children more than 2 years of age the previously
watchful guidelines can be maintained but some flexibility
is recommended [22, 36].
Treatment of OME: tympanostomy tubes?
The approach to OME must take into account the natural
history of spontaneous healing and the main complication
which is temporary hearing impairment [1]. The absence of
spontaneous healing after 6 weeks to 2 months in children
over 2 years of age is an indication for a 10-day antibiotic
course according to the results of the nasopharyngeal
aspirate cultures. It is our experience that this approach
has several advantages. First, the effect even temporarily on
the hearing defect is frequently successful. Second, it
decreases the recurrence of AOM by improving the ET
functions and third, it allows postponement or avoidance of
tympanostomy tube insertion, because improved hearing
points to improved permeability of the ET.
The delay of 6 weeks or 2 months before treatment of
OME (Table 2) is based on the duration of OME. Indeed, in
a prospective study by Renko et al. [43] of 90 children with
AOM, 0.6–7 years of age, treated with amoxicillin or
cefuroxime axetil for 10 days, the mean duration of OME
was 10.2 days (range: 1–58 days); only 10 of 90 still had
OME after 29–43 days.
In a long-term prospective study in 6,350 healthy infants
treated according to specified guidelines, Paradise et al. [38]
observed bilateral OME in only 5.6% of the 161 children
who had not received tympanostomy tubes at the age of 4.
The indication to insert tubes is equivocal. The large
prospective studies on 3,686 infants and young children by
the Paradise group have shown the absence of or negligible
effects of tympanostomies on developmental outcomes at
3–4 years [34, 37]. On the other hand, insertion of
tympanostomy tubes during the first 3 years of life is
associated with complications in at least 80% of the patients
[63]. Tympanostomy can be a source of bacterial infections
[24] and of tympanosclerosis.
Extensive reviews by Kubba et al. [25], Rosenfeld et al.
[46], Rovers et al. [48] and the recent Cochrane Database
by Lous et al. [30] concluded that there was only a small
benefit of the conventional ventilation tube. The main
reason for the poor results of tympanostomy tubes is the
absence of effects on the ET dysfunction. It has never been
demonstrated that tympanostomy tubes improve the func-
tions of the ET.
The recommendations by the American Academy of
Pediatrics [1] are to insert tubes in conditions with
persisting hearing loss of more than 40 dB particularly
Table 2 Guidelines for treatment of OME. SMZ sulfamethoxazole, TMP trimethoprim
Indication Approach Treatment
Without deafness “Watchful waiting” approach
With deafness After 6 weeks-2 months
in children ≥2 years
Amoxicillin 90 mg/kg per day or amoxicillin 90 mg/kg per day + clavulanic acid
6.4 mg/kg per day for 10 days according to the results of the bacterial resistance
No swimming
Recurrent OME or OME
of long duration
Azithromycin 10 mg/kg per day, 3 days/week for 4 weeks
Cotrimoxazole 30 mg SMZ + 6 mg TMP/kg per day according to the results of the
bacterial resistance
Adenoidectomy in children ≥3 years of age with nasopharyngeal obstruction and
recurrent adenoiditis
No swimming
516 Eur J Pediatr (2007) 166:511–519with posterosuperior retraction pockets, ossicular erosions
and adhesive atelectasis because of the increase of
structural damage with effusion duration.
Watchful waiting for 3–6 months in the winter period
seems advisable in children with mild hearing deficit.
Adenoidectomy should be considered in children
≥3 years of age with nasopharyngeal obstruction and
recurrent adenoiditis [45].
Vaccination
The effects of pneumococcal vaccination on recurrent
AOM have been studied extensively. In a randomized
controlled trial by Brouwer et al. [6] in 383 children, aged
1–7 years, with recurrent AOM, the effects in 190 children
treated with heptavalent pneumococcal vaccine were
compared with 193 children receiving hepatitis A or B
vaccines. The study concluded that there was no beneficial
effect. A similar conclusion was drawn from a study by Van
Kempen et al. [62] in 74 children aged 1–7 years and in the
Cochrane Database by Straetemans et al. [56].
A shift of the causative pathogen has been observed
from Streptococcus pneumoniae to Haemophilus influenzae
or to other strains of pneumococci than the ones included in
the vaccine [20, 59]. A slight reduction of the incidence of
AOM of 6–8% was observed in the USA [7].
Infants and prematures
A high incidence of OME has been observed in neonatal
intensive care units due to the nasally placed tubes for
ventilatory assistance. It has been suggested that immune
immaturity with impaired neuromotor function predisposes
to this complication [17]. Vaccination with the heptavalent
pneumococcal vaccine has been advocated in premature
babies and neonates [19], but this study does not provide
information on the actual AOM prevalence in a control
group receiving only hepatitis B vaccine. It should be
remembered that meconium aspiration into the entry of the
middle ear is associated with increased risk of AOM and
therefore early nasopharyngeal suction is mandatory [29].
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